Cloning of genetically tagged chromosome break sequences reveals new fragile sites at 6p21 and 13q22

International Journal of Cancer

Volumn 120, Issue 11, 2007, Pages 2359-2367

  Fechter, Anne ^a   Buettel, Isabel ^a   Kuehnel, Elisabeth ^a   Schwab, Manfred ^a   Savelyeva, Larissa ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chromosome rearrangements; FRA6H; Fragile site; FRAI3E; Genomic instability

Indexed keywords

ARTICLE; BREAST CANCER; CHROMOSOME 13Q; CHROMOSOME 6P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITE; CHROMOSOME MAP; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MAPPING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MARKER GENE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS;

BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 6; CLONING, MOLECULAR; DNA PRIMERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 34247372140     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22564     Document Type: Article

References (71)

1. Berger R, Bloomfield CD, Sutherland GR. Report of the Committee on Chromosome Rearrangements in Neoplasia and on Fragile Sites. Cytogenet Cell Genet 1985;40:490-535.
2. Glover TW, Arlt MF, Casper AM, Durkin SG. Mechanisms of common fragile site instability. Hum Mol Genet 2005;14 (Spec No. 2): R197-R205.
3. n. Science 1991;252:1711-14.
4. Jones C, Slijepcevic P, Marsh S, Baker E, Langdon WY, Richards RI, Tunnacliffe A. Physical linkage of the fragile site FRA11B and a Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Mol Genet 1994;3:2123-30.
5. Yu S, Mangelsdorf M, Hewett D, Hobson L, Baker E, Eyre HJ, Lapsys N, Le Paslier D, Doggett NA, Sutherland GR, Richards RI. Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell 1997;88:367-74.
6. Hewett DR, Handt O, Hobson L, Mangelsdorf M, Eyre HJ, Baker E, Sutherland GR, Schuffenhauer S, Mao JI, Richards RI. FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Mol Cell 1998;1:773-81.
7. Schwartz M, Zlotorynski E, Kerem B. The molecular basis of common and rare fragile sites. Cancer Lett 2006;232:13-26.
8. Hormozian F, Schmitt JG, Sagulenko E, Schwab M, Savelyeva L. FRA1E common fragile site breaks map within a 370 kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD). Cancer Lett 2007;296:82-91.
9. Helmrich A, Stout-Weider K, Matthaei A, Hermann K, Heiden T, Schrock E. Identification of the human/mouse syntenic common fragile site FRA7K/Fra12C1-Relation of FRA7K and other human common fragile sites on chromosome 7 to evolutionary breakpoints. Int J Cancer 2007;120:48-54.
10. Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A, Kerem B. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 2006;13:1057-59.
11. Fechter A, Buettel I, Kuehnel E, Savelyeva L, Schwab M. Common fragile site FRA11G and rare fragile site FRA11B at 11q23.3 encompass distinct genomic regions. Genes Chromosomes Cancer 2007;46: 98-106.
12. Savelyeva L, Sagulenko E, Schmitt JG, Schwab M. The neurobeachin gene spans the common fragile site FRA13A. Hum Genet 2006; 118:551-58.
13. Mishmar D, Rahat A, Scherer SW, Nyakatura G, Hinzmann B, Kohwi Y, Mandel-Gutfroind Y, Lee JR, Drescher B, Sas DE, Margalit H, Platzer M, et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci USA 1998;95:8141-6.
14. Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E, Hershberg R, Levi A, Scherer SW, Margalit H, Kerem B. Molecular basis for expression of common and rare fragile sites. Mol Cell Biol 2003;23: 7143-51.
15. Hellmah A, Rahat A, Scherer SW, Darvasi A, Tsui LC, Kerem B. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol 2000;20:4420-7.
16. Le Beau MM, Rassool FV, Neilly ME, Espinosa R, III, Glover TW, Smith DI, McKeithan TW. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 1998;7:755-61.
17. Palakodeti A, Han Y, Jiang Y, Le Beau MM. The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer 2004;39:71-76.
18. Debatisse M, El Achkar E, Dutrillaux B. Common fragile sites nested at the interfaces of early and late-replicating chromosome bands: cis acting components of the G2/M checkpoint? Cell Cycle 2006;5:578-81.
19. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-89.
20. Musio A, Montagna C, Mariani T, Tilenni M, Focarelli ML, Brait L, Indino E, Benedetti PA, Chessa L, Albertini A, Ried T, Vezzoni P. SMC1 involvement in fragile site expression. Hum Mol Genet 2005; 14:525-33.
21. Arlt MF, Xu B, Durkin SG, Casper AM, Kastan MB, Glover TW. BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol Cell Biol 2004;24:6701-9.
22. Howlett NG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005;14:693-701.
23. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006;25:4381-8.
24. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev 2005;19:2715-26.
25. Büttel I, Fechter A, Schwab M. Common fragile sites and cancer: targeted cloning by insertional mutagenesis. Ann NY Acad Sci 2004;1028: 14-27.
26. Popescu NC, Zimonjic D, DiPaolo JA. Viral integration, fragile sites, and proto-oncogenes in human neoplasia. Hum Genet 1990;84:383-6.
27. Rassool FV, McKeithan TW, Neilly ME, van Melle E, Espinosa R, III, Le Beau MM. Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites. Proc Natl Acad Sci USA 1991;88:6657-61,
28. Thorland EC, Myers SL, Persing DH, Sarkar G, McGovern RM, Gostout BS, Smith DI. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res 2000;60:5916-21.
29. Miguez L, Fuster C, Perez MM, Miro R, Egozcue J. Spontaneous chromosome fragility in chorionic villus cells. Early Hum Dev 1991;26:93-9.
30. Gollin SM, Bock HG, Caskey CT, Ledbetter DH. A new family with fra(10)(q25): spontaneous expression and 100% expression with 100 microM BrdU. Am J Med Genet 1985;21:643-8.
31. Taylor AM, Bundey S. Spontaneous expression of the chromosome fragile site fra(10)(q25). Am J Hum Genet 1983;35:123-5.
32. Bruun D, Folias A, Akkari Y, Cox Y, Olson S, Moses R. siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells. DNA Repair (Amst) 2003;2:1007-13.
33. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-5.
34. Turner BC, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner CL, Sevignani C, Aldaz CM, McCue PA, Palazzo J, Huebner K, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 2002;62:4054-60.
35. Matzner I, Savelyeva L, Schwab M. Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell line. Cancer Lett 2003;189:207-19.
36. Sbrana I, Zavattari P, Barale R, Musio A. Common fragile sites on human chromosomes represent transcriptionally active regions: evidence from camptothecin. Hum Genet 1998;102:409-14.
37. Minami M, Poussin K, Brechot C, Paterlini P. A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Genomics 1995;29:403-8.
38. Hubbard T, Andrews D, Caccamo M, Cameron G, Chen Y, Clamp M, Clarke L, Coates G, Cox T, Cunningham F, Curwen V, Cutts T, et al. Ensembl 2005. Nucleic Acids Res 2005;33:D447-D453.
39. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, et al. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 1996;380:152-4.
40. Henegariu O, Bray-Ward P, Ward DC. Custom fluorescent-nucleotide synthesis as an alternative method for nucleic acid labeling. Nat Biotechnol 2000;18:345-8.
41. Becker NA, Thorland EC, Denison SR, Phillips LA, Smith DI. Evidence that instability within the FRA3B region extends four megabases. Oncogene 2002;21:8713-22.
42. Ferber MJ; Thorland EC, Brink AA, Rapp AK, Phillips LA, McGovern R, Gostout BS, Cheung TH, Chung TK, Fu WY, Smith DI: Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene 2003;22:7233-42.
43. Rassool FV, Le Beau MM, Shen ML, Neilly ME, Espinosa R, III, Ong ST, Boldog F, Drabkin H, McCarroll R, McKeithan TW. Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2. Genomics 1996;35:109-17.
44. Thorland EC, Myers SL, Gostout BS, Smith DI. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 2003;22:1225-37.
45. Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 2004;110:701-9.
46. Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI. The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 2005;158:27-34.
47. Bauer-Hofmann R, Borghouts C, Auvinen E, Bourda E, Rosl F, Alonso A. Genomic cloning and characterization of the nonoccupied allele corresponding to the integration site of human papillomavirus type 16 DNA in the cervical cancer cell line SiHa. Virology 1996; 217:33-41.
48. Glover TW, Berger C, Coyle J, Echo B. DNA polymerase a inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 1984;67:136-42.
49. Rocchi A, Pelliccia F. Synergistic effect of DAPI and thymidylate stress conditions on the induction of common fragile sites. Cytogenet Cell Genet 1988;48:51-4.
50. Kormann-Bortolotto MH, Smith Mde A, Toniolo Neto J. Fragile sites, Alzheimer's disease, and aging. Mech Ageing Dev 1992;65:9-15.
51. Smeets DF, Merkx G. Neither age nor sex influence the expression of folate sensitive common fragile sites on human chromosomes. Hum Genet 1990;86:76-8.
52. Smith MA, Borsatto B. Down's syndrome, ageing and fragile sites. Mech Ageing Dev 1998;101:167-73.
53. Tedeschi B, Vernole P, Sanna ML, Nicoletti B. Population cytogenetics of aphidicolin-induced fragile sites. Hum Genet 1992;89:543-7.
54. Green RJ, Phillips DL, Chen AT, Reidy JA, Ragab AH. Effects of folate in culture medium on common fragile sites in lymphocyte chromosomes from normal and leukemic children. Hum Genet 1988;81: 9-12.
55. Musio A, Sbrana I. Aphidicolin-sensitive specific common fragile sites: a biomarker of exposure to pesticides. Environ Mol Mutagen 1997;29:250-5.
56. Hecht F, Tajara EH, Lockwood D, Sandberg AA, Hecht BK. New common fragile sites. Cancer Genet Cytogenet 1988;33:1-9.
57. Yunis JJ, Soreng AL, Bowe AE. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1987;1:59-69.
58. Mornet E, Crete P, Kuttenn F, Raux-Demay MC, Boue J, White PC, Boue A. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet 1991;48:79-88.
59. Micci F, Panagopoulos I, Bjerkehagen B, Heim S. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 2006;66:107-12.
60. Lim G, Karaskova J, Beheshti B, Vukovic B, Bayani J, Selvarajah S, Watson SK, Lam WL, Zielenska M, Squire JA. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 2005;42:392-403.
61. Matteucci C, La Starza R, Crescenzi B, Falzetti D, Romoli S, Emiliani C, Orlacchio A, Marynen P, Martelli MF, Mecucci C. Interpretation of the complex karyotype and identification of a new 6p amplicon by integrated comparative genomic hybridization and fluorescence in situ hybridization on the U937-I cell line. Cancer Genet Cytogenet 2002; 135:28-34.
62. Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, Ferron A, Garrido F. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004;56:244-53.
63. Inoue M, Marx A, Zettl A, Strobel P, Muller-Hermelink HK, Starostik P. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002;161:1507-13.
64. Chatterjee A, Pulido HA, Koul S, Beleno N, Perilla A, Posso H, Manusukhani M, Murty VV. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res 2001;61:2119-23.
65. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, de Weger R, Tilanus M. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999;54:235-45.
66. Nagai H, Kihoshita T, Suzuki H, Hatano S, Murate T, Saito H. Identification and mapping of novel tumor suppressor loci on 6p in diffuse large B-cell non-Hodgkin's lymphoma. Genes Chromosomes Cancer 1999;25:277-83.
67. Mazurenko N, Attaleb M, Gritsko T, Semjonova L, Pavlova L, Sakharova O, Kisseljov F. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep 1999;6:859-63.
68. Kainu T, Juo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi OP, Tirkkonen M, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 2000;97:9603-8.
69. Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF, Jr. Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 2000;60:3880-3.
70. Rivas F, Rivera H, Plascencia ML, Ibarra B, Cantu JM. The phenotype in partial 13q trisomies, apropos of a familial (13;15)(q22;q26) translocation. Hum Genet 1984;67:86-93.
71. Xu J, Chernos JE, Bernier F, Lowry RB. Characterization of an interstitial deletion del(13)(q22q32) using microdissection and sequential FISH and G-banding. Genet Test 2000;4:279-82.